<DOC>
	<DOC>NCT03012490</DOC>
	<brief_summary>The primary objective is to determine whether comprehensive remote follow-up in HF patients with CRT will reduce the combined endpoint of all-cause mortality or worsening heart failure hospitalizations, whichever comes first, when compared to basic remote monitoring, over a 27-month follow-up.</brief_summary>
	<brief_title>Efficacy, Safety and Cost of Remote Monitoring of Patients With Cardiac Resynchronization Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient more than 18 years old, newly implanted, in accordance to the latest European guidelines, with a CRTP or CRTD device (upgrading is tolerated but no device replacement), with HomeMonitoringÂ® activated Patient willing and able to comply with the protocol and who has provided written informed consent Lead model under advisory Nonfunctional lead except particular case of nonfunctional or deactivated right atrial lead due to atrial fibrillation Known drug or alcohol abuse Pregnant woman or woman who plan to become pregnant during the trial (the data will be collected by querying the patient without a pregnancy test is required) Participation (ongoing or planned during the trial) in another interventional clinical study, and/or another remote monitoring and/or followup concept, unless authorized by the Executive Committee Participation (ongoing or planned during the trial) in an investigational HF program (e.g. PRADO, PIMPS, OSICAT, CARDIAUVERGNE) Estimated lifeexpectancy, regardless of the cardiovascular condition, &lt;1year Patient under or planned for ventricular assistance Patient not living in Metropolitan France and/or not geographically stable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Remote monitoring</keyword>
</DOC>